CJC-1295 (no DAC) 10mg Dosage & Mixing Guide

What is CJC-1295 (no DAC)?

CJC-1295 without DAC, also known as Mod GRF 1-29 or Modified GRF (1-29), is a synthetic analog of growth hormone-releasing hormone (GHRH). It consists of the first 29 amino acids of GHRH with four amino acid substitutions that improve stability and half-life.

Important distinction: CJC-1295 exists in two forms:

• CJC-1295 no DAC (Mod GRF 1-29): Shorter half-life (~30 minutes), pulsatile release
• CJC-1295 with DAC: Drug Affinity Complex extends half-life to ~8 days, continuous release — covered separately in the CJC-1295 DAC guide

This guide covers the no DAC version, which is more commonly used in research due to its ability to maintain natural pulsatile GH patterns. The 10mg vial is the bulk presentation; the 5mg vial covers the same ground at half the mass.

Quick Reference

Reconstitution Guide

Materials Needed

• CJC-1295 (no DAC) 10mg lyophilized vial
• Bacteriostatic water (BAC water)
• Insulin syringes (U-100, 29-31 gauge)
• Alcohol swabs
• Sharps container

Step-by-Step Instructions

1. Prepare workspace — Clean area, gather all materials, wash hands.

2. Clean vial stoppers — Alcohol swab both vials. Allow to dry.

3. Draw BAC water — Draw 4mL bacteriostatic water into syringe. This will usually take two passes with a 3mL syringe; add the water in stages rather than forcing one large transfer.

4. Add to peptide — Inject slowly down inside wall of vial. Avoid direct contact with powder.

5. Dissolve — Allow 2-3 minutes for dissolution. Gentle swirl if needed. The larger powder cake may take slightly longer than a 5mg vial.

6. Verify — Solution should be completely clear.

7. Label and store — Date vial and refrigerate immediately.

Note: CJC-1295 no DAC is more fragile than some peptides — handle carefully and use within 2-3 weeks of reconstitution. Because 10mg is more than a typical 2-3 week protocol consumes, some researchers reconstitute in smaller portions and keep the remainder lyophilized at -20°C.

Dosage Protocol

Concentration Calculations

With 10mg peptide in 4mL BAC water:

• Concentration: 2.5mg/mL = 2500mcg/mL
• Per unit (U-100 syringe): 25mcg per unit

Common Dose Calculations

If you want the same 2mg/mL concentration as the 5mg vial so both sizes share one dose table, use 5mL of BAC water instead. Units then become dose / 20 on a U-100 syringe.

Suggested Research Protocols

Standalone Protocol:

• Dose: 100-200mcg
• Frequency: 2-3x daily
• Timing: Morning, post-workout, bedtime
• Duration: 12-16 weeks

Combined Protocol (with Ipamorelin):

• CJC-1295 no DAC: 100mcg
• Ipamorelin: 200mcg
• Frequency: 2-3x daily
• Duration: 12-16 weeks
• Note: GHRH + GHRP synergy

Timing Optimization

Avoid: Administering within 2 hours of meals

Injection Guide

Subcutaneous Administration

1. Clean injection site with alcohol
2. Pinch skin at abdomen, thigh, or arm
3. Insert needle at 45-90° angle
4. Inject slowly and steadily
5. Wait 5 seconds before withdrawing

Site Rotation

Standard rotation:

• Abdomen (most common)
• Outer thigh
• Back of upper arm

Storage Requirements

Lyophilized (Powder)

• Temperature: -20°C (-4°F) or colder
• Duration: 2+ years
• Conditions: Dry, dark, airtight

Reconstituted

• Temperature: 2-8°C (36-46°F)
• Duration: 2-3 weeks (shorter than some peptides)
• Conditions: Refrigerated, protected from light

Important: CJC-1295 no DAC has a shorter reconstituted stability than many peptides. Use within 2-3 weeks. At 300-600mcg per day the 10mg vial holds well over a month of material, so plan the reconstitution volume around the window rather than the vial.

Research Considerations

Mechanism of Action

CJC-1295 no DAC works through:

• GHRH receptor activation: Stimulates pituitary somatotrophs
• Pulsatile GH release: Short half-life creates distinct pulses
• Preserved feedback: Maintains physiological regulation
• IGF-1 elevation: Secondary to GH increase

No DAC vs With DAC

The 10mg size is more common in the no-DAC form precisely because the dosing frequency is higher — the same vial mass goes much further in a weekly DAC protocol.

Synergy with GHRPs

The combination of GHRH (CJC-1295) + GHRP (Ipamorelin) produces synergistic effects:

• GHRH primes the pituitary
• GHRP amplifies the release
• Combined response > sum of individual responses
• Research shows 2-3x amplification

Saturation Considerations

Research suggests:

• 100mcg may approach saturation per dose
• Higher single doses show diminishing returns
• Multiple daily doses more effective than single large dose
• Individual response varies significantly

Common Combinations

CJC-1295 no DAC + Ipamorelin: Most popular research combination. Clean GH release profile.

CJC-1295 no DAC + GHRP-2: Stronger GH release but increased hunger/cortisol.

CJC-1295 no DAC + GHRP-6: Potent combination with significant appetite stimulation.

Sourcing for Research

Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.

Scientific References

1. Alba M, et al. “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.” Am J Physiol Endocrinol Metab. 2006;291:E1290-E1294.
2. Ionescu M, Bhaumick B. “GHRH analogs: current and future perspectives.” Mol Cell Endocrinol. 2002;197:75-81.
3. Teichman SL, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295.” J Clin Endocrinol Metab. 2006;91:799-805.

Last updated: July 21, 2026

Disclaimer: This information is for educational and research purposes only. CJC-1295 is a research chemical not intended for human consumption. Always follow applicable laws and institutional guidelines.